AIDS Therapies

Unusual New NNRTI Has Dual Anti-HIV Activity

Published in AIDS Weekly, November 8th, 1999

by Daniel J. DeNoon, Senior Editor -- A new non-nucleoside reverse transcriptase inhibitor (NNRTI) not only exquisitely inhibits HIV reverse transcription - with a jaw-dropping therapeutic index of more than 4 million - but also prevents the virus from entering cells.

Thus the compound, dubbed SJ-3366 by Samjin Pharmaceutical Co. Ltd., Seoul, Korea, is the first NNRTI to inhibit both HIV-1 and HIV-2.

"Based on its significantly elevated therapeutic index, SJ-3366 represents an exciting new compound for use in HIV infected individuals," suggested R.W. Buckheit of the Southern Research Institute, Frederick, Maryland.

Buckheit and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-11-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry